These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 11587226)
21. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. Quackenbush RC; Reuther GW; Miller JP; Courtney KD; Pear WS; Pendergast AM Blood; 2000 May; 95(9):2913-21. PubMed ID: 10779439 [TBL] [Abstract][Full Text] [Related]
22. Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. Chalandon Y; Jiang X; Hazlewood G; Loutet S; Conneally E; Eaves A; Eaves C Blood; 2002 May; 99(9):3197-204. PubMed ID: 11964283 [TBL] [Abstract][Full Text] [Related]
24. Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Jiang X; Stuible M; Chalandon Y; Li A; Chan WY; Eisterer W; Krystal G; Eaves A; Eaves C Blood; 2003 Oct; 102(8):2976-84. PubMed ID: 12829595 [TBL] [Abstract][Full Text] [Related]
25. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model. Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417 [TBL] [Abstract][Full Text] [Related]
26. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Salgia R; Quackenbush E; Lin J; Souchkova N; Sattler M; Ewaniuk DS; Klucher KM; Daley GQ; Kraeft SK; Sackstein R; Alyea EP; von Andrian UH; Chen LB; Gutierrez-Ramos JC; Pendergast AM; Griffin JD Blood; 1999 Dec; 94(12):4233-46. PubMed ID: 10590068 [TBL] [Abstract][Full Text] [Related]
27. SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Chen J; Yu WM; Daino H; Broxmeyer HE; Druker BJ; Qu CK Blood; 2007 Jan; 109(2):778-85. PubMed ID: 17003374 [TBL] [Abstract][Full Text] [Related]
28. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]. Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985 [TBL] [Abstract][Full Text] [Related]
29. [Establishment of mouse SP2/0 cell line stably expressing bcr-abl fusion gene fragment]. Jiang YW; Qian L; Liu W; Gong WJ; Wang B; Guan J; Ji MC Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):601-4. PubMed ID: 16129042 [TBL] [Abstract][Full Text] [Related]
30. [TEC promoter mediates P210(bcr/abl) gene expression in BaF3 cells]. Zhu YF; Wang YZ; Meng FY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):769-72. PubMed ID: 22739199 [TBL] [Abstract][Full Text] [Related]
31. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. Elefanty AG; Hariharan IK; Cory S EMBO J; 1990 Apr; 9(4):1069-78. PubMed ID: 1691092 [TBL] [Abstract][Full Text] [Related]
32. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia. García-Tuñón I; Hernández-Sánchez M; Ordoñez JL; Alonso-Pérez V; Álamo-Quijada M; Benito R; Guerrero C; Hernández-Rivas JM; Sánchez-Martín M Oncotarget; 2017 Apr; 8(16):26027-26040. PubMed ID: 28212528 [TBL] [Abstract][Full Text] [Related]
33. Doxycycline regulation in a single retroviral vector by an autoregulatory loop facilitates controlled gene expression in liver cells. Kühnel F; Fritsch C; Krause S; Mundt B; Wirth T; Paul Y; Malek NP; Zender L; Manns MP; Kubicka S Nucleic Acids Res; 2004 Feb; 32(3):e30. PubMed ID: 14966262 [TBL] [Abstract][Full Text] [Related]
34. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226 [TBL] [Abstract][Full Text] [Related]
35. Models of chronic myeloid leukemia. Van Etten RA Curr Oncol Rep; 2001 May; 3(3):228-37. PubMed ID: 11296133 [TBL] [Abstract][Full Text] [Related]
36. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research. Peng C; Li S Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931 [TBL] [Abstract][Full Text] [Related]
39. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging]. Wu Y; Chen YZ; Huang HF; Chen P; Lu LH Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661 [TBL] [Abstract][Full Text] [Related]
40. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Jiang X; Ng E; Yip C; Eisterer W; Chalandon Y; Stuible M; Eaves A; Eaves CJ Blood; 2002 Nov; 100(10):3731-40. PubMed ID: 12393460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]